Working… Menu

Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial (Shock n Block)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00401882
Recruitment Status : Terminated (Difficult accrual)
First Posted : November 22, 2006
Results First Posted : March 31, 2017
Last Update Posted : May 25, 2017
Medtronic BRC
Information provided by (Responsible Party):
David Haines, MD, William Beaumont Hospitals

Brief Summary:
The purpose of this research study is to evaluate the effectiveness of metoprolol, a "beta blocker," in treating patients in the hospital with a cardiac arrest. It will be given intravenously (given into a vein). The subjects who will take part in this study are 18 years of age or older, are experiencing a cardiac arrest in the hospital, and are in a life threatening situation. Patients who develop a cardiac arrest require prompt electrical defibrillation (electrical shocks) to restore the normal beating rhythm of the heart. In patients who do not respond to electrical defibrillation, current standard of care recommends the use of medications which have been shown to be of unknown benefit. Some people recover from a cardiac arrest, but many people do not. We want to learn whether giving metoprolol will improve survival of patients with a cardiac arrest. A total of 100 patients will be enrolled in the study. Patients will receive either the standard of care with the drug epinephrine or the standard of care plus metoprolol.

Condition or disease Intervention/treatment Phase
Cardiac Arrest Sudden Cardiac Death Ventricular Fibrillation Tachycardia, Ventricular Drug: Epinephrine Drug: Metoprolol Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial
Study Start Date : January 2007
Actual Primary Completion Date : June 2011
Actual Study Completion Date : March 2012

Arm Intervention/treatment
Active Comparator: Standard Of Care Drug Epinephrine
Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
Drug: Epinephrine
Epinephrine (1 mg) IV additional doses
Other Name: adrenaline

Active Comparator: IV Metoprolol instead Epinephrine
IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
Drug: Metoprolol
Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
Other Name: lopressor

Primary Outcome Measures :
  1. Return of Spontaneous Circulation [ Time Frame: After electrical defibrillation ]
    The patient will be evaluated for sufficiently stable and organized rhythm and blood pressure.

Secondary Outcome Measures :
  1. Survival to Hospital Discharge [ Time Frame: from time of arrest to discharge or death ]
    the number of patients who are alive at hospital discharge

  2. Adverse Effects [ Time Frame: 30 days ]
  3. Number of Precordial Shocks Required After the Administration of Metoprolol or Epinephrine [ Time Frame: 120 minutes ]
  4. Total Duration of Resuscitative Efforts [ Time Frame: 120 minutes ]
  5. Need for Additional Antiarrhythmic Drugs [ Time Frame: 120 minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients age > 18 years of age who develop an in-hospital VF or pVT arrest which persists after three or more precordial shocks.
  • Patients who develop an in-hospital cardiac arrest due to asystole or PEA which subsequently converts to VF or pVT will be included.

Exclusion Criteria:

  • Pediatric patients
  • Pregnancy
  • Age < 18 years of age
  • Patients who develop VF or pVT in the emergency room, operating room or surgical intensive care unit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00401882

Layout table for location information
United States, Michigan
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
Sponsors and Collaborators
David Haines, MD
Medtronic BRC
Layout table for investigator information
Principal Investigator: David E Haines, MD William Beaumont Hospitals

Layout table for additonal information
Responsible Party: David Haines, MD, Coordinator, William Beaumont Hospitals Identifier: NCT00401882     History of Changes
Other Study ID Numbers: 2006-008
First Posted: November 22, 2006    Key Record Dates
Results First Posted: March 31, 2017
Last Update Posted: May 25, 2017
Last Verified: March 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Keywords provided by David Haines, MD, William Beaumont Hospitals:
Cardiac arrest
Sudden Cardiac Death
Ventricular Fibrillation
Pulseless Ventricular Tachycardia
Cardiopulmonary resuscitation
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Arrest
Death, Sudden, Cardiac
Ventricular Fibrillation
Tachycardia, Ventricular
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Cardiac Conduction System Disease
Death, Sudden
Epinephryl borate
Adrenergic beta-Antagonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents